• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc (NQ: CMND )

    1.250 +0.020 (+1.63%)
    Streaming Delayed Price Updated: 3:14 PM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 14,513,656
    Open 1.430
    Bid (Size) 1.250 (5)
    Ask (Size) 1.270 (12)
    Prev. Close 1.230
    Today's Range 1.150 - 1.460
    52wk Range 0.1000 - 6.800
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024
    Clearmind Medicine just reported results for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -55.04%
    -55.04%
    1 Month
    +4.17%
    +4.17%
    3 Month
    +2.46%
    +2.46%
    6 Month
    -58.33%
    -58.33%
    1 Year
    +139.74%
    +139.74%

    More News

    Read More
    What's Going On With Clearmind Medicine Stock Tuesday?
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Clearmind Medicine Stock Is Moving Higher
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Applies to Cease Being a Reporting Issuer in Canada
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine CEO Issues Letter to Shareholders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
    Via Benzinga
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
    Via Benzinga
    Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
    Via Benzinga
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.